BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20798194)

  • 1. Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial.
    Pronzato P; Cortesi E; van der Rijt CC; Bols A; Moreno-Nogueira JA; de Oliveira CF; Barrett-Lee P; Ostler PJ; Rosso R;
    Oncologist; 2010; 15(9):935-43. PubMed ID: 20798194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
    Hudis CA; Vogel CL; Gralow JR; Williams D;
    Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
    Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
    J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
    Cortesi E; Mancuso A; De Pasquale Ceratti A; Pizzardi N; D'Auria G; Accettura C; Beccaglia P; Bertelletti D; De Marinis F
    Oncologist; 2004; 9(4):459-68. PubMed ID: 15266099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy.
    Bajetta E; Vercammen E; Reinhardt U; Janmohamed R; da Costa RM; Matulonis U; Guastalla JP;
    Tumori; 2004; 90(5):449-57. PubMed ID: 15656327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
    Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
    J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
    Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
    J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
    Chang J; Couture F; Young S; McWatters KL; Lau CY
    J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
    Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
    Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.
    O'Shaughnessy JA; Vukelja SJ; Holmes FA; Savin M; Jones M; Royall D; George M; Von Hoff D
    Clin Breast Cancer; 2005 Feb; 5(6):439-46. PubMed ID: 15748464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
    Straus DJ; Testa MA; Sarokhan BJ; Czuczman MS; Tulpule A; Turner RR; Riggs SA
    Cancer; 2006 Oct; 107(8):1909-17. PubMed ID: 16977654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis.
    Jones M; Schenkel B; Just J; Fallowfield L
    Cancer; 2004 Oct; 101(8):1720-32. PubMed ID: 15386341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.
    Campos SM; Duh MS; Lefebvre P; Rosberg J
    J Natl Compr Canc Netw; 2005 Nov; 3(6):807-16. PubMed ID: 16316616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin alfa in patients not on chemotherapy - Canadian data.
    Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F
    Semin Oncol; 2002 Jun; 29(3 Suppl 8):75-80. PubMed ID: 12082658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM; Yee L; Gabrail N; Charu V; Tomita D; Rossi G; Schwartzberg L
    Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
    Abdelrazik N; Fouda M
    Hematology; 2007 Dec; 12(6):533-41. PubMed ID: 17852440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.